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Abstract The sphingolipid composition and multidrug resis-
tance status of three human neuroblastoma cell lines were es-
tablished. SK-N-FI cells displayed high expression and function-
al (e¥ux) activity of P-glycoprotein, while multidrug resistance-
related protein 1 was relatively abundant and most active in SK-
N-AS cells. These two cell lines exhibited higher sphingolipid
levels, compared to SK-N-DZ, which had the lowest activity of
either ATP-binding cassette transporter protein. SK-N-DZ cells
also di¡ered in ganglioside composition with predominant ex-
pression of b-series gangliosides. In conclusion, these three neu-
roblastoma cell lines o¡er a good model system to study sphin-
golipid metabolism in relation to ATP-binding cassette
transporter protein function.
) 2003 Published by Elsevier Science B.V. on behalf of the
Federation of European Biochemical Societies.
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1. Introduction
Treatment failure in neuroblastoma, one of the most com-
mon extracranial solid tumors in childhood, is often due to
the occurrence of multidrug resistance (MDR). A large variety
of MDR mechanisms exists, including the overexpression of
energy-dependent drug e¥ux proteins, such as P-glycoprotein
(Pgp) and multidrug resistance-related protein 1 (MRP1) [1].
Moreover, it has become apparent that sphingolipids and
their metabolism play a role in drug resistance, possibly in
concert with ATP-binding cassette (ABC) transporter proteins
[2^4]. Evidence for a relation between MDR and sphingolip-
ids has come from studies in tumor cell lines, which acquired
a drug resistant phenotype by selection with cytotoxic agents.
The level of glucosylceramide (GlcCer), a precursor of all
complex glycosphingolipids and a direct metabolic product
of ceramide (Cer), was consistently elevated in several Pgp
overexpressing cell lines [5]. A similar GlcCer increase was
observed in the MRP1 overexpressing HT29col cell line [6].
It has even been suggested to consider increased GlcCer levels
as a diagnostic marker for MDR tumors [7].
Little is known concerning the mechanisms underlying
MDR-associated sphingolipid changes, but these may depend
on cell type. It has been suggested that increased conversion
of Cer to GlcCer by glucosylceramide synthase (GCS) in Pgp
overexpressing MCF-7 cells rescues cells from cytostatic-in-
duced Cer-mediated apoptosis [8,9]. On the other hand, in
Pgp overexpressing 2780AD cells, uncoupling of GlcCer and
lactosylceramide (LacCer) biosynthesis in the Golgi apparatus
leads to accumulation of GlcCer, without changes in GCS
expression or activity [10]. It is therefore important to explore
MDR-associated changes in sphingolipid composition in a
wide variety of tumor cells with variable expression of ABC
transporter proteins.
In this study we have characterized both the MDR status
and the sphingolipid composition of three human neuroblas-
toma cell lines, SK-N-AS, SK-N-DZ and SK-N-FI. These cell
lines o¡er the advantage that their MDR properties have
emerged in vivo, in contrast to in vitro drug selection models.
In the latter multiple cellular adaptations may have been co-
selected. An additional advantage of these cell lines is their
high content of complex glycosphingolipids, e.g. gangliosides
[11]. Although gangliosides have only rarely been associated
with MDR, a recent study in human myeloblastic KG1a/200
cells shows GM3- and GD3-induced phosphorylation of Pgp
on serine residues, thereby modulating its activity [12].
Our results in these neuroblastoma cell lines show that dif-
ferential neutral sphingolipid and ganglioside metabolism oc-
cur in a background of di¡erential Pgp and MRP1 expression
and activity, acquired in vivo. As such, this contributes to our
knowledge of MDR-associated sphingolipid metabolism. In
addition, this o¡ers a good model to study the contribution
of speci¢c sphingolipids, including speci¢c gangliosides, to
drug resistance of tumor cells.
2. Materials and methods
2.1. Cell culture conditions
Human neuroblastoma cell lines SK-N-AS, SK-N-DZ and SK-N-
FI were purchased from the ATCC (Manassas, VA, USA). They were
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grown as adherent monolayer cultures in Dulbecco’s modi¢ed Eagle’s
medium (Gibco, Life Technologies BV, Breda, The Netherlands) sup-
plemented with 10% fetal calf serum (Bodinco, Alkmaar, The Nether-
lands), 100 units/ml penicillin (Gibco), 100 Wg/ml streptomycin (Gib-
co) and non-essential amino acids (Gibco), under standard incubator
conditions (humidi¢ed atmosphere, 95% air, 5% CO2, 37‡C).
2.2. Detection of Pgp and MRP1 expression by Western blot analysis
Western blot analysis was performed as described [6]. Brie£y, cells
were washed and subjected to protein content determination (Biorad,
Veenendaal, The Netherlands). Ten Wg of protein dissolved in sample
bu¡er was heated for 5 min at 95‡C (except MRP1 samples), loaded
and run on SDS^PAGE (sodium dodecyl sulfate^polyacrylamide gel
electrophoresis; 10%) mini-gels. Proteins were electrotransferred onto
Immobilon-P PVDF. For detection, primary mouse anti-Pgp, C219
(Signet-Sanbio B.V., Uden, The Netherlands), 1:300 or rat anti-
MRP1, MRPr1 (Signet-Sanbio B.V.), 1:1000 antibodies and second-
ary alkaline phophatase-conjugated sheep anti-mouse (Pgp) or anti-
rat (MRP1) IgG antibodies (Boehringer Mannheim GmbH, Mann-
heim, Germany) were used. Immunoreactive proteins were detected
using p-nitroblue tetrazolium and 5-bromo-4-chloro-3-indolyl phos-
phate as substrates.
2.3. Measurement of cellular sensitivity to cytotoxic drugs
(MTT assay)
Fifteen thousand cells/well were plated in microtiter plates. Cyto-
statics were added 4 h after plating. Ninety-six hours after plating
viability of the cells was determined as previously described [13].
Brie£y, 100 Wg of MTT (Sigma, St. Louis, MO, USA) was added to
each well and cells were incubated for 3.5 h at 37‡C. Plates were then
centrifuged (15 min, 900Ug) and the supernatants were removed.
Pellets were dissolved in DMSO and absorbencies were measured in
a microtiter plate reader (WQuant, Bio-Tek Instruments, Winooski,
VT, USA) at a V of 570 nm. The background absorbency was sub-
tracted from all values and data were expressed as percentage com-
pared to untreated control cells ( = 100%). IC50 values ( = drug con-
centration which results in viability reduction of 50%) were
determined directly from the dose^response curves.
2.4. Detection of Pgp and MRP1-mediated drug e¥ux by FACS
analysis
Cells (1U106 in HBSS) were incubated for 60 min at 37‡C in the
presence of the Pgp substrate Rhodamine 123 (Rh123, 10 WM, Sigma)
or the MRP1 substrate 5-carboxy£uorescein diacetate (CFDA, 0.5
WM, Sigma) and in the presence ‘(+/+)’ or absence ‘(3/3)’ of the
Pgp inhibitor cyclosporin A (CSA, 10 WM, Alexis, Carlsbad, CA,
USA) or the MRP1 inhibitor MK571 (20 WM). After loading, cells
were washed with ice-cold bu¡er and incubated for 60 min (Pgp) or 45
min (MRP1) at 37‡C (e¥ux) in the presence (+/+) or absence (3/3)
of inhibitor. Subsequently, e¥ux was stopped by replacement with
ice-cold bu¡er and Rh123/CF £uorescence was measured by £ow cy-
tometry (FACSCalibur; Becton Dickinson, Franklin Lakes, NJ,
USA). For each sample 5000 events were collected and analyzed using
Win-list 5.0 software (Verity Software House Inc., Topsham, ME,
USA), which resulted in median relative £uorescence units (F.U.).
From these data the e¥ux-blocking factor (BF) was calculated, which
is de¢ned as:
BF ¼ ½F:U: in ðþ=þÞcells3F:U: in untreated cells½F:U: in ð3=3Þcells3F:U: in untreated cells
2.5. Equilibrium radiolabeling and analysis of cellular sphingolipids
Sphingolipid pools were metabolically radiolabeled to equilibrium
as described [10]. Cells were grown for 48 h in the presence of L-[U-
14C]serine (1 WCi/ml; Amersham International, Bercks, UK), har-
vested and subjected to lipid extraction [14]. Acylglycerolipids were
hydrolyzed during 1 h incubation at 37‡C in CHCl3/CH3OH (1:1, v/v)
containing NaOH (0.1 M). The remaining lipids were re-extracted and
applied on high-performance thin layer chromatography (HPTLC)
plates (Merck, Amsterdam, The Netherlands). Plates were developed
in CHCl3/CH3OH/H2O (14:6:1, v/v/v) in the ¢rst dimension and in
CHCl3/CH3COOH (9:1, v/v) in the second dimension. After scraping
of the Cer containing spots, the plates were sprayed with 2.5% H3BO3
(w/v) in CH3OH and developed once more in the second dimension,
this time using CHCl3/CH3OH/25% (w/v) NH4OH (13:7:1, v/v/v) as
the mobile phase. GlcCer, galactosylceramide (GalCer), LacCer, and
sphingomyelin (SM) containing spots were scraped from the plates.
Radioactivity was measured by scintillation counting (Packard Top-
count microplate scintillation counter, Meriden, CT, USA). Lipid
levels were expressed as dps incorporated in a speci¢c lipid species
per 103 dps of total lipid-incorporated radioactivity, as measured after
the initial lipid extraction.
2.6. Measurement of C5-Bodipy-labeled sphingolipids
Cells were washed three times with HBSS and incubated in the
presence of C5-Bodipy-ceramide (4 WM; Molecular Probes Europe
BV, Leiden, The Netherlands) at 37‡C for 3 h. After washing, cells
were scraped, the protein content was determined and lipids were
extracted [14]. Extracted lipids were applied to HPTLC plates and
run in CHCl3/CH3OH/NH4OH/H2O (60:40:4:1; v/v/v/v). Individual
spots were scraped, suspended in a 1% (v/v) Triton X-100 solution
(2 ml), and shaken vigorously for 1 h. After centrifugation, £uores-
cence in the supernatants was measured (Vex = 505 nm; Vem = 511 nm;
SLM Aminco SPF-500, Urbana, IL, USA), by reference to a standard
curve of a known amount of C5-Bodipy-Cer.
2.7. Mass analysis of gangliosides
Gangliosides were isolated from 5^7U107 cells, as described [15,16].
Brie£y, pelleted cells were extracted in CHCl3/CH3OH (1:1; v/v) and
CHCl3/CH3OH (2:1; v/v). Pooled supernatants were dried (N2) and
the lipids were dissolved and sonicated in CHCl3/CH3OH (1:1; v/v).
After centrifugation and overnight storage at 320‡C, the supernatant
was dried, dissolved in diisopropylether/1-butanol (3:2; v/v), and 17
mM NaCl was added. The aqueous phase was re-extracted with dii-
sopropylether/1-butanol and subsequently lyophilized. Samples were
dissolved in CH3OH/H2O (1:1; v/v) and loaded onto pre-washed Sep-
Table 1
E¥ux-blocking factors (BF) for Pgp and MRP1 in human neuroblastoma cell lines
BF P-values
Pgp MRP1 Pgp MRP1
SK-N-AS 2.2W 0.4 26.7W 18.2 AS v DZ 0.02 0.03
SK-N-DZ 1.7W 0.3 5.3 W 2.9 AS v FI 6 0.001 0.01
SK-N-FI 86.0W 23.9 8.5 W 2.6 DZ v FI 6 0.001 0.07
Cells were loaded with either Rh123 (10 WM) or CFDA (0.5 WM) for 60 min at 37‡C or 10‡C, followed by e¥ux in the presence or absence of
the inhibitors CSA (10 WM) or MK571 (20 WM) for 60 min or 45 min at 37‡C. BF were calculated as described in Section 2. Data represent
the meanWS.D. of four independent experiments.
Fig. 1. Western blot of relative Pgp or MRP1 expression levels in
human neuroblastoma cell lines. Equal amounts of protein were
loaded on the gel. The sizes of the Pgp and MRP1 proteins are 170
and 190 kDa, respectively. Shown are representative results from at
least three independent experiments.
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Pak C18 (Waters, Milford, MA, USA) cartridges. After rinsing (H2O),
gangliosides were eluted with CH3OH and CHCl3/CH3OH (1:1; v/v).
The eluate was concentrated and loaded onto HPTLC plates, which
were developed in CHCl3/CH3OH/0.2% (w/v) CaCl2 (11:9:2; v/v/v)
and stained with Ehrlich reagent [17]. Gangliosides were quanti¢ed by
densitometry, involving analysis with Scion Image Beta 4.0.2 (Scion
Corporation, Frederick, MD, USA) software of a scanned image of
the HPTLC.
2.8. Statistical analysis
Results are presented as meanWS.D. (nv 4). Statistical analysis was
performed with the Student’s t-test, considering P6 0.05 signi¢cant.
3. Results
3.1. Di¡erential Pgp and MRP1 expression and e¥ux activity
in SK-N-FI, SK-N-DZ and SK-N-AS
Western blotting analysis revealed the relative expression
levels of Pgp and MRP1 in three human neuroblastoma cell
lines (Fig. 1). Pgp expression was high in SK-N-FI, and low in
SK-N-AS. In contrast, MRP1 expression was highest in SK-
N-AS and lowest in SK-N-FI. SK-N-DZ displayed intermedi-
ate levels of both ABC transporters. In accordance, signi¢cant
(Rh123) e¥ux activity of Pgp was observed in SK-N-FI cells
only (Table 1). Moreover, signi¢cant functional activity of
MRP1 was found in SK-N-AS, while SK-N-FI and SK-N-
DZ displayed residual e¥ux activity.
3.2. Functional activity of ABC transporters is correlated with
resistance to multiple cytotoxic drugs
The impact of functional (e¥ux) activity of ABC transport-
ers on drug resistance was explored by means of cytotoxicity
assays. The three cell lines were exposed to taxol, vincristine,
etoposide and doxorubicin, which have all been recognized as
Pgp substrates. Accordingly, the Pgp expressing SK-N-FI dis-
played relatively high resistance to all four cytostatic drugs,
with high IC50 values (Table 2). The MRP1 expressing SK-N-
AS was less resistant even though MRP1 is able to transport
vincristine, etoposide and doxorubicin. Least resistance was
displayed by SK-N-DZ, which lacked signi¢cant functional
activity of either Pgp or MRP1.
In conclusion, the highest expression levels and activities of
Pgp and MRP1 were found in the SK-N-FI and SK-N-AS cell
lines, respectively. This expression correlated well with the
degree of drug resistance displayed by these neuroblastoma
cell lines, compared to SK-N-DZ, and suggests a prominent
role for ABC transporters, especially Pgp, in drug resistance
of these cell lines.
3.3. Analysis of the sphingolipid composition in SK-N-AS,
SK-N-DZ and SK-N-FI cells
Sphingolipid biosynthesis was studied by incubating the
cells with C5-Bodipy-Cer. A relatively high conversion to
both C5-Bodipy-GlcCer and C5-Bodipy-SM was observed in
both SK-N-FI and SK-N-AS, as compared to SK-N-DZ (Ta-
ble 3A). The high conversion to C5-Bodipy-SM correlated
well with high endogenous levels of SM in SK-N-FI and es-
pecially SK-N-AS, as measured by equilibrium radiolabeling
(Table 3B). Endogenous GlcCer, which is known to be asso-
ciated with MDR, is more abundant as well in the resistant
Table 2
IC50 values for taxol, vincristine, etoposide and doxorubicin as determined with the MTT cell survival assay
Taxol (nM) Vincristine (ng/ml) Etoposide (ng/ml) Doxorubicin (nM)
SK-N-AS 6.8W 3.5 0.8W 0.3 875W 114 291W 72
SK-N-DZ 2.0W 0.1 0.9W 0.2 213W 6 85W 5
SK-N-FI s 50 s 30 s 1000 s 1000
SK-N-AS, SK-N-DZ and SK-N-FI were exposed to increasing concentrations of taxol (0^50 nM), vincristine (0^30 ng/ml), etoposide (0^1000
ng/ml) and doxorubicin (0^1000 nM) for 96 h. Data represent the meanWS.D. of four or more than four independent experiments, each con-
sisting of two replicate determinations.
Fig. 2. A^C: Ganglioside patterns of the human neuroblastoma cell lines SK-N-FI, SK-N-DZ and SK-N-AS, respectively. Reference ganglio-
sides (ref) and the relative amount of gangliosides per cell line are displayed next to these patterns. Ganglioside quanti¢cation was done by
densitometry. The cell lines SK-N-FI (89%) and SK-N-AS (79%) predominantly express a-series gangliosides (GM3, GM2, GM1 and GD1a),
while b-series gangliosides (GD3, GD2, GD1a and GT1b) are the major products (62%) of the SK-N-DZ cell line. Gangliosides were isolated
from aliquots of cells with equal protein content. Shown are representative results from three independent experiments.
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SK-N-FI and SK-N-AS, as compared to the relatively chemo-
sensitive SK-N-DZ.
The three cell lines were also analyzed for their ganglioside
composition (Fig. 2). High levels of a-series (i.e. GM3, GM2,
GM1 and GD1a) gangliosides were found in SK-N-FI (Fig.
2A) and SK-N-AS (Fig. 2C). In contrast, the SK-N-DZ (Fig.
2B) expressed predominantly b-series gangliosides (GD3,
GD2, GD1b and GT1b).
4. Discussion
It has been shown that in vitro established Pgp [5,10] and
MRP1 [6] overexpressing tumor cell lines display enhanced
levels of the sphingolipid GlcCer. Moreover, these studies
showed that in addition to changes in the level of GlcCer,
other sphingolipid levels are altered in MDR tumor cells,
however in a cell-type-dependent fashion. In the present
study, we analyzed the composition and metabolism of sphin-
golipids in neuroblastoma cell lines, which di¡er from the
previously studied models in the sense that MDR acquisition
and ABC transporter expression were attained in vivo, and
thus more resemble naturally occurring adaptations. In this
model, an enhanced GlcCer level also parallels expression of
functionally active ABC transporters, and additional changes
in sphingolipid composition occur as well. A novel ¢nding in
the current model is that expression of ABC transporters is
correlated with overall enhanced levels and biosynthesis of
sphingolipids, while a dichotomy is observed with respect to
the biosynthetic pathway of choice. Although Pgp is expressed
in all three neuroblastoma cell lines, it is functionally active
only in SK-N-FI and this is correlated with channelling of
sphingolipid metabolism into glycolipids. MRP1 is also ex-
pressed in all three cell lines, but functional activity only oc-
curs in SK-N-AS. The latter is correlated with channeling of
sphingolipid metabolism towards SM biosynthesis. A direct
causal relationship between sphingolipid metabolism and
ABC transporter expression/function remains to be proven.
With respect to the downstream metabolic products of
GlcCer, such as gangliosides, di¡erences were also observed
between functionally active ABC transporter expressing neu-
roblastoma cells and SK-N-DZ cells. The high expression of
GD2, as occurs in SK-N-DZ, is generally associated with
more aggressive forms of neuroblastoma, but relations to
drug resistance are unknown. A functional role for ganglio-
sides in MDR is only recently emerging. Certain gangliosides
(GM3, GD3) may be directly involved in MDR by modula-
tion of Pgp function through alteration of its phosphorylation
state [12]. Consistent with this notion, our preliminary results
in the SK-N-AS cell line show that long-term (5 days) inhibi-
tion of glycolipid synthesis by incubation with 1-phenyl-2-
hexadecanoylamino-3-pyrrolidino-1-propanol results in a 30%
decrease of MRP1-mediated CF e¥ux (data not shown).
Recently, up-regulation of ganglioside biosynthesis at the level
of GM3 biosynthesis was shown to occur in fenretinide-
adapted A2780 cells, and was correlated with fenretinide re-
sistance [18]. Due to the novelty of this particular research
area and the limited studies and results available, a consistent
picture concerning the contribution of speci¢c gangliosides to
MDR has not yet emerged.
In conclusion, the three neuroblastoma cell lines character-
ized in this study o¡er a good model to further dissect the
roles of speci¢c sphingolipids and their metabolism in MDR
at various levels of sphingolipid metabolic pathways and
against a background of either one of the two most estab-
lished MDR-associated functional ABC transporters.
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